Stock ONCONOVA THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Onconova Therapeutics Inc Nasdaq

Equities

US68232V1089

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Traws Pharma Files for Potential Sale of 128.9 Million Shares
MT
Traws Pharma, Inc. Announces Resignation of Steven M. Fruchtman as President and Chief Scientific Officer, Oncology
CI
Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir
PU
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
GL
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Traws Pharma : Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies
PU
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
GL
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
CI
North American Morning Briefing : Focus Turns to -2-
DJ
Traws Pharma, Inc. Announces Chief Executive Office Changes
CI
Traws Pharma, Inc. Announces Board Changes
CI
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics
MT
Transcript : Onconova Therapeutics, Inc. - M&A Call
Traws Pharma Announces New Employee Inducement Grants
AQ
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
AQ
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc
CI
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.
CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. Stock
  5. News Onconova Therapeutics Inc